"Unsere Praxis besteht seit 1997 und ist seitdem etablierte Behandlungsstätte für onkologische und hämatologische Erkrankungen. Seit April 2009 arbeiten wir in modernen Praxisräumen im Medicinum. Wir arbeiten nach der Qualitätsmanagement-Richtlinie des Gemeinsamen Bundesausschusses. Zur kontinuierlichen Verbesserung unsere Arbeit nutzen wir das von der Kassenärztlichen Bundesvereinigung speziell für die Anforderungen in der ambulanten Patientenversorgung entwickelte Qualitätsmanagementverfahren QEP (Qualität und Entwicklung in Praxen). Die umfassende Betreuung unserer Patienten ist für uns Verpflichtung zu einer fachübergreifenden kollegialen Zusammenarbeit mit allen beteiligten Ärzten der Kliniken und Praxen."

During the past decade, Onkologische Schwerpunktpraxis im Medicinum conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis im Medicinum" #1 collaborator was "Roche Pharma AG" with 2 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Onkologische Schwerpunktpraxis im Medicinum" are "Advanced Solid Tumors or Hematologic Malignancies" (1 trials) and "Metastatic Colorectal Cancer" (1 trials). Many other conditions were trialed in "Onkologische Schwerpunktpraxis im Medicinum" in a lesser frequency.

Most popular intervention types in "Onkologische Schwerpunktpraxis im Medicinum" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan" (1 trials) and "Oxaliplatin, 5FU/LV, Bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Onkologische Schwerpunktpraxis im Medicinum" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Onkologische Schwerpunktpraxis im Medicinum". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Onkologische Schwerpunktpraxis im Medicinum, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Onkologische Schwerpunktpraxis im Medicinum, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".